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Abstract 
 
Aims: 
Merkel cell carcinoma, a rare cutaneous neuroendocrine tumor of the skin, can be 
categorized into two groups according to Merkel cell polyomavirus (MCV) presence. MCV-
negative tumors are more aggressive and frequently associated with gene mutations. Some 
of the genes are potential therapeutic targets. We have previously reported EGFR mutations 
in 6/27 MCC tumors and overexpression of ALK and EZH2 at mRNA level in MCC tumors. In 
this study, we sought to determine expression of ALK, EGFR and EZH2 in MCC samples and 
assess their correlation to MCV status and clinical parameters. 
Methods and results: 
Tissue microarrays were utilized and stained with primary antibodies. Staining data was 
statistically compared to patient sex, tumor location and development of metastasis and 
MCC specific death. 112 tumors and their corresponding patient data were included. We 
found strong expression of ALK in 51% and strong expression of EZH2 in 76% of the tumors. 
There was evident correlation of ALK expression with MCV-positivity. Expression of EGFR 
was infrequent presenting only in 7 MCV-negative tumors. None of the proteins associated 
with development of metastasis or MCC specific death.  
Conclusions: 
ALK and EZH2 expression are frequent in MCC and ALK expression correlates to MCV 
positivity. EGFR positive tumors might respond to EGFR inhibiting treatment.  
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Introduction  
 
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer categorized into 
two groups according to the presence of the Merkel cell Polyomavirus (MCV). 1-4 MCC has a 
tendency to metastasize; it spreads to the lymph nodes more often than other skin 
malignancies. 5 Notably, MCV-negative tumors seem to be the more aggressive as compared 
with MCV-positive tumors. 6, 7 
We have previously studied MCC tumors for aberrations in cancer-related genes utilizing 
targeted next-generation sequencing (NGS). The most intriguing findings of our NGS studies 
were mutations of the EGFR gene in 22% of 27 MCC tumors, and overexpression of ALK and 
EZH2 at mRNA level in MCC tumors as compared to normal skin. 8, 9 Most of the EGFR 
mutations we detected are previously reported in non-small cell lung cancer 10 and at least 
one of the mutations has been reported to be responsive to EGFR inhibitor treatment in 
lung  adenocarcinoma. 11 EGFR and ALK are transmembrane receptor tyrosine kinases 
involved in many types of cancer, for example non-small cell lung cancer. 12-16 ALK is named 
after its involvement in a fusion protein discovered in anaplastic large cell lymphomas. 17 
There is no evidence of activating ALK mutations 8, 18, 19  or fusions 9, 20 in previous literature 
regarding MCC and therefore the mechanism of ALK overexpression is unknown. EZH2 is an 
enzyme that silences gene function by promoting DNA heterochromatin formation. It is 
normally expressed during fetal development, but expression of EZH2 is found in various 
types of cancer, and the role of EZH2 inhibitors in cancer therapy is under investigation, with 
multiple ongoing preclinical projects 21 while at least one phase I study regarding B-cell 
lymphoma and epithelioid sarcoma is completed. 22  
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MCV-positive and MCV-negative tumors have distinct pathological characteristics; therefore 
it is rational to seek for molecular aberrations in subsets of MCC tumors that would 
potentially benefit from certain targeted therapy. Mutational studies indicate that especially 
MCV-negative tumors are associated with more gene mutations, the  majority of which are 
caused by UV radiation. Some of these mutated genes are considered potential targets of 
therapy for certain MCC tumors. 8, 18, 19, 23 Based on our previous results, in this current study 
we sought to determine expression of ALK, EGFR and EZH2 by immunohistochemistry in a 
large tumor cohort and assess their correlation to the tumor MCV status and potential 
prognostic or therapeutic value of these proteins.  
 
Materials and Methods 
 
The Ethics Committee of Helsinki University Hospital approved the study. The Ministry of 
Health and Social Affairs granted permission to gather patient data, and the National 
Authority for Medicolegal Affairs to collect and analyze tumor samples. Clinical data 
gathered for this study included patient age at diagnosis, sex, location of primary tumor and 
information on whether the patient developed metastasis or died for MCC. The clinical 
details were gathered for these patients as they were in 12th June 2013 and no further 
follow-up was conducted.  
 
Tissue micro arrays (TMA) were constructed from our nationwide pool of formalin-fixed 
paraffin-embedded (FFPE) MCC tumor samples. MCC diagnoses were confirmed by clinical 
characteristics and microscopic morphology compatible with cutaneous MCC and by 
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immunohistochemistry positive for CK-20 and negative for TTF-1. MCV status of the tumors 
was determined by quantitative PCR as described in detail elsewhere. 24 From the FFPE 
tumor samples, representative tumor regions were first defined from H&E-stained sections 
and marked. A 0.6-mm tissue cores of each tumor sample was inserted into an empty well 
on the tissue array block. Two cores per tumor was included at initial construction. 3 μm 
sections were cut from the TMA block and processed for immunohistochemistry.  
 
For immunohistochemical stainings, a Ventana Benchmark Ultra instrument (Roche, Tucson, 
AZ, USA) was utilized for ALK-1 (clone D5F3, Roche 790-4794) and EGFR (clone 5B7, Roche 
790-4347) RTU antibodies. For pretreatment of these antibodies we used Cell Conditioning 1 
buffer, pH8.5, (Roche 950–124), 64 min in 98 °C. The incubation time for ALK-1 was 28 
min/36°C and for EGFR 20min/36°C. The multimer based detection kit, OptiView, (Roche 
760–700), was used to detect the antibodies.  An amplification step was added for both 
protocols by using separated an amplification kit (Roche 760–099). Lung adenocarcinoma 
tissue with EML4-ALK translocation confirmed by FISH as well as anaplastic large cell 
lymphoma tissue with NPM1-ALK translocation confirmed by FISH was used as a positive 
control for ALK staining while the negative controls were lung adenocarcinoma and ALCL 
samples without the mentioned chromosome rearrangements. For EGFR, normal epidermis 
as well as human placenta were used as positive controls. The EZH2 staining (clone 11/EZH2, 
BD Transduction 612666, USA) was performed in the LabVision immunostainer (Labvision, 
CA, USA). Antigen retrieval was done by using the Tris-EDTA buffer, pH 9.0 (in a PT- module 
for 20 minutes in 98°C). For detection, we applied the polymer-based detection system 
(Envision, K5007, Agilent, USA). DAB was applied as a chromogen for all of the antibodies 
and the slides were stained with hematoxylin (Mayer, S3099, Agilent, USA).  
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Immunohistochemical stainings were interpreted by two researchers (TV and TB). Individual 
samples on the TMA slides were disqualified if the sample was partly or completely missing 
or technically excluded during the construction process, if the sample did not include tumor 
tissue or if the  MCV-status of the tumor was unknown. The exact number of included 
samples varied from 110-111 between stained TMA slides, but altogether  there were 112 
tumors that had successful staining with at least 2 of the antibodies and therefore were 
included in the further analysis. Regarding ALK and EZH2 IHC, there was large variation of 
staining intensity between individual samples, and thus based on the intensity of staining, 
expression of ALK and EZH2 was interpreted as either negative, weak positive or strong 
positive.  (Figures 1 and 3) In contrast, EGFR expression was simply interpreted either 
negative or positive. (Figure 2) 
 
Statistical analysis to correlate protein expression to MCV status and clinical data was done 
with  the Chi-Squared and Fisher’s exact test. The Chi-Squared test was also utilized to 
correlate the presence of metastasis during the follow-up to MCC specific death. To analyze 
the relationship of protein expression and MCC-specific death, the survival was estimated  
with the Kaplan-Meier method and the logrank test was used to compare the survival 
between the groups. MCC specific survival was calculated from the date of diagnosis to date 
of death from MCC. P-values less than 0.05 were considered significant. Statistics were done 
with NCSS statistical software (NCSS, LCC.). The Kaplan-Meier plots are presented in 
supplementary material. 
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Results 
This study included TMAs containing 112 Merkel cell carcinoma tumor samples with 
respective clinical data. Of those 112 patients, 30 (27 %) were males and 82 (73 %) females. 
The mean age of the patients was 78 years. Over half of the tumors, 60 (54%) were located 
in the head and neck region. 31 tumors were MCV-negative (28%) and 81 MCV-positive 
(72%). Distant metastasis was present in 28 cases (25%), while 11 cases (9.8%) had only local 
lymph node involvement. At the end of follow-up for this patient cohort, 20% had died from 
MCC. The presence of distant metastasis during the follow-up was significantly correlated to 
MCC specific death (p-value < 0.00001). Immunohistochemical staining results in 
comparison to MCV status is presented in Table 1.  
 
ALK expression 
ALK expression was successfully analyzed in 110 tumor samples. Two of the tumors had 
corrupted ALK staining on the TMA slides. From the 110 tumors, 56 were strongly positive 
for ALK and 16 weak positive (51% and 15% respectively). 38 (34%) tumors were negative 
for ALK.  (Figure 4) 
We recorded clear correlation between ALK expression and MCV-positivity; From the 79 
MCV-positive tumors 66 were positive for ALK (84%) and 65% were strong positives, while in 
the MCV-negative cohort only  10 of 31 tumors were ALK positive (32%) and 16% were 
strong positives. This correlation  ALK expression and MCV positivity was statistically 
significant (p 0.000006). However, ALK expression did not correlate with patient sex, tumor 
location or development of metastasis or MCC specific death.  
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EGFR expression  
111 tumors were analyzed for EGFR and only 7 (6.3%) were positive for EGFR. Notably all 
EGFR positive tumors were MCV-negative and 22% of the 31 MCV-negative tumors 
expressed EGFR. (p 0.000011 and 0.000077 respectively). (Figure 5) We were unable to find 
significant correlation with EGFR expression to sex, location, metastasis or MCC specific 
death. Although there was slight orientation to more severe course of disease since 3 out of 
7 EGFR positive tumors developed metastasis and died from MCC. However, this 
observation was not statistically significant.  
 
EZH2 expression 
Our examination revealed abundant expression of EZH2 in MCC tumors. 84 (76 %) tumors 
out of 111 showed strong positivity, while 18 (%) tumors were weak positive, and only 9 
(8%) were negative. EZH2 expression was not related to tumor MCV-status or any of the 
clinical parameters that were analyzed.  
 
Discussion 
 
Herein, we studied the immunohistochemical expression of ALK, EGFR and EZH2 in 112 
Merkel cell carcinoma TMA cores. We showed that ALK expression is common in MCC, 
although less frequent than previously reported. The intensity of ALK expression seemed to 
vary between the ALK positive samples. We did not establish correlation between ALK 
immunopositivity and clinical characteristics. However, we showed evident correlation of 
ALK expression and tumor MCV-positivity. The correlation was particularly apparent with 
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tumors that expressed strong ALK positivity, since 91% of them were MCV-positive. It is 
uncharted whether ALK and MCV are interacting, but it could be that the MCV promotes 
ALK expression via an unknown mechanism.  
 
We have previously studied ALK in MCC tumors and found strong expression of ALK at 
mRNA and protein level.  9 In our previous study, we applied fluorescence in situ 
hybridization to seek for chromosomal translocations, but no fusions of ALK were 
uncovered. 9 In previously conducted immunohistochemistry studies, ALK expression has 
been frequent in MCC, however no correlation to tumor MCV status has been reported. 
Filtenborg-Barnkob et al. reported ALK expression frequency as high as 93.8% on 32 MCC 
tumors, and our group also recorded ALK positivity in 22 of 24 MCC tumors examined 
(91,7%). 9, 20 
Based on available literature, MCC tumors lack EGFR expression. 25 In our previous studies 
we recorded under expression of EGFR at mRNA level in MCC tumors compared to normal 
skin 9, and in keeping with other work, found no immunohistochemical EGFR positivity in 
any of the MCC tumors studied. Yet, we discovered EGFR mutations in 22% of 27 MCC 
tumors 8 . This encouraged us to explore the expression of EGFR in a greater tumor 
multitude.  In this paper we demonstrated that a small number of MCC (6%) were EGFR 
positive and significantly all of them were MCV-negative. We even observed possible 
association between EGFR positivity and metastasis development and death from MCC, but 
the association was not statistically significant. Since the low number of EGFR positive cases 
causes a challenge in analyzing correlations to clinical data, more numerous tumor cohorts 
are required to further assess this potential correlation.  
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In contrast to our previous study where we did not find EGFR positivity in MCC tumors by 
IHC with the antibody clone 31G7, which reacts with the extracellular domain of EGFR, 8, we 
now used a different EGFR antibody, clone 5B7, which binds to the intracellular domain of 
EGFR and also detects truncated forms of the receptor that are constitutively active. 26 The 
clone 5B7 has been used to detect expression of EGFR in non-small cell lung cancer TMA 
samples and was found to predict response to an EGFR Tyrosine Kinase inhibitor treatment. 
26, 27 We therefore suggest that the small subset of MCC tumors that are EGFR positive and 
MCV-negative, might benefit from EGFR inhibitor treatment, and they could be identified 
with a relatively easy and cost effective method like IHC.  
 
We earlier reported EZH2 expression at mRNA level in MCC tumors 9. In addition, there has 
been activating EZH2 mutation in 1 MCC tumor out of 15 tumors studied 28, however, other 
mutational studies on MCC have not recorded EZH2 mutations. 8, 18, 19   A recent study by 
Harms et al. suggested that EZH2 could be a prognostic factor in MCC. Higher expression of 
EZH2 correlated with worse 5-year MCC-specific survival. 29 Correspondingly to their study, 
we observed frequent expression of EZH2 in MCC tumors (92%), and the intensity of the 
expression varied between the tumors. Therefore, we categorized the positivity either weak 
or strong. However, our cohort also displayed 8 % completely negative tumors. Contrary to 
Harms et al, we only examined primary MCC tumors, while their cohort included tumor 
metastases. We did not identify correlation between primary tumor EZH2 expression and 
development of metastasis or MCC-specific death. Therefore, usability of EZH2 as a 
prognostic factor is yet uncertain. However, since the majority of MCC tumors are EZH2 
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positive, it could be a  potential therapeutic target, and clinical trials with forthcoming EZH2 
inhibitors would be recommended.  
 
A current trend in cancer research and treatment is to go deeper into individual tumors 
characteristics and develop personalized treatment for cancer patients. 30 Conventional drug 
trials conducted in large patient cohorts fail to demonstrate efficacy of treatments that only 
affect a certain group of patients. A particular challenge with MCC is that firstly it is rare and 
secondly, part of the tumors are associated with MCV and therefore embody distinct 
pathologic properties. Gaining knowledge of genetic and molecular alterations in MCV-
positive and MCV-negative tumors poses an opportunity to determine tumors that might 
benefit from already existing treatments such as tyrosine kinase inhibitors, for example. Our 
vision is that future clinical trials for advanced MCC should take into account the individual 
molecular characteristics of the tumor.  
 
We conclude that protein expression in MCV-positive and MCV-negative tumors is diverse 
and also  differs in individual tumors. ALK expression correlates to MCV-positivity, while 
EZH2 expression is frequent regardless of MCV-status. A subset of MCV-negative tumors 
express EGFR and might respond to EGFR TKI treatment.  
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Table 1. Number and percentages of MCV-negative and MCV-positive tumors with certain staining 
result. 
 MCV 
ALK Negative Positive Total 
 STRONG 5 (9 %) 51 (91 %) 56 
 WEAK 5 (31 %) 11 (69 %) 16 
 NEGATIVE 21 (55 %) 17 (45 %) 38 
       TOTAL 31 (28 %) 79 (72 %) 110 
EGFR    
 POSITIVE 7 (100 %) 0 (0 %) 7 
 NEGATIVE 24 (23 %) 80 (77 %) 104 
       TOTAL 31 (28 %) 80 (72 %) 111 
EZH2    
 STRONG 22 (26 %) 62 (74 %) 84 
 WEAK 6 (33 %) 12 (67 %) 18 
 NEGATIVE 3 (33 %) 6 (67 %) 9 
       TOTAL 31 (28 %) 80 (72 %) 111 
 
Figure legends 
Figure 1: ALK expression by immunohistochemistry. Upper panel shows strong positive 
staining while lower panel represents weak positive staining. 200x magnification. 
Figure 2: EGFR expression by immunohistochemistry. Upper panel shows positive staining 
while lower represents apparent negative staining. 200x magnification. 
Figure 3: EZH2 expression by immunohistochemistry. Upper panel shows strong positive 
staining while lower panel represents weak positive staining. 200x magnification. 
Figure 4: Frequency of ALK positive and negative MCC samples in comparison to MCV status. 
Strong positives are marked “+” and weak negatives “(+)”. 
Figure 5: Frequency of EGFR positive and negative MCC samples in comparison to MCV 
status. 
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